Compare Pfizer Inc (PFE) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Wynn Resorts, Limited — how do they compare? Pfizer Inc trades at $28.01 (market cap $158.56B), while Wynn Resorts, Limited trades at $75.65 (market cap $7.75B). The key difference: Pfizer Inc is far larger — about 20.5× Wynn Resorts, Limited's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Wynn Resorts, Limited for 76 Days on average.
| PFE | WYNN | |
|---|---|---|
Market Cap | $158.56B | $7.75B |
Volume | 44,138,282 | 2,243,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $133.09 |
52-Week Low | $23.67 | $74.97 |
Typical Hold Time | 158 Days | 76 Days |
Enterprise Value | $210.06B | $17.99B |
Dividend Yield | 6.18% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Wynn Resorts (WYNN) trades at $74.97, down 2.15% today, with a bearish technical signal despite bullish oscillators. The company reported mixed Q2 2026 results, beating EPS estimates but facing margin pressures. Revenue reached $7.14B in 2025, though net income declined to $327M. Analysts maintain a strong buy consensus with a $132.36 price target, while institutional activity shows mixed positioning amid high debt levels and significant capital expenditure plans.
The outlook for WYNN hinges on Macau recovery and successful execution of UAE expansion, but rising capex and debt servicing costs pose risks. Current valuation metrics appear reasonable with P/E of 18.06 and EV/EBITDA of 9.23, though investors should monitor margin trends and project timelines closely given the stock's significant discount to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
